Translating blood biomarkers into the clinic for neurodegenerative diseases with Henrik Zetterberg

Video Journal of Biomedicine | Expert Perspective

Tremendous efforts have been made in the last few years with regards to blood biomarkers for neurodegenerative diseases. From the discovery of serum neurofilament light as a sensitive biomarker for neuronal loss to advancements in imaging techniques, the field is moving forward at an extremely quick pace. In this interview, Henrik Zetterberg (UCL Queen Square Institute of Neurology, London, UK) provides his insights into the current status of this field, how the challenges surrounding replication and reproducibility might be addressed and the issues around specificity with serum neurofilament light.

About the author:

Henrik Zetterberg, MD, PhD, is Professor of Neurochemistry at the University of Gothenburg, Sweden, and at University College London, UK, as well as the Head of the Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy at the University of Gothenburg, Sweden. With a background in molecular biology and medicine, Dr. Zetterberg has spent the past 10 years focusing on the development of biomarkers for Alzheimer’s disease and other brain disorders. His research involves evaluation of biomarkers in cell and animal models, as well as in longitudinal studies of patients and healthy individuals. He has published more than 300 scientific articles and has received the Erik K. Fernström prize for young scientists and the Inga Sandeborg prize for research on Alzheimer’s disease.

Original publication:

Video originally published on Neuro Central, a digital platform from the Future Science Group that unites all aspects of neurology and neuroscience.